Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NCT00819169 · NantCell, Inc. · PHASE1/PHASE2 · terminated · last registry update 2024-08-20 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision - subjects rolled over to protocol 20101116” | Open Targets' class: study design | Registry record, NantCell, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGF1R in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-09-25Results posted on the registry: NantCell, Inc., AMG 479 + AMG 479 (NCT00807612)
- 2024-09-25Also stopped (terminated): NantCell, Inc., AMG 479 + AMG 479 (NCT00807612)
- 2024-08-23Results posted on the registry: NantCell, Inc., AMG 479 + Etoposide (NCT00791154)
- 2024-08-23Also stopped (terminated): NantCell, Inc., AMG 479 + Etoposide (NCT00791154)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision